Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
The Food and Drug Administration (FDA) is amending its current good manufacturing practice (CGMP) regulations for human drugs, including biological products, to exempt most investigational "Phase 1" drugs from complying with the requirements in FDA's regulations. FDA will instead exercise oversight of production of these drugs under the agency's general statutory CGMP authority and investigational new drug application (IND) authority. In addition, FDA is making available simultaneously with the publication of this direct final rule, a guidance document setting forth recommendations on approaches to CGMP compliance for the exempted Phase 1 drugs. Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed rule, under FDA's usual procedure for notice-and-comment rulemaking, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule. The companion proposed rule and direct final rule are substantively identical. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a draft guidance for industry entitled "INDs--Approaches to Complying With CGMP During Phase 1" to provide further guidance on the subject.
D019985:Benchmarking; D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence*; D017321:Clinical Trials, Phase I as Topic; D004349:Drug Packaging / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000592:standards*; D017408:Guidelines as Topic; D006801:Humans; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence*; D012449:Safety / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational